CMS 024-02, with the common name of Tyroservatide, is used for the treatment of non-small cell lung cancer. In October 2005, it was approved for Phase I clinical trial, which lasted from March 2006 to November 2006. At present, Phase II clinical trial is in the process of application.

The Phase I clinical trial of CMS 024-02 was completed and the result proves that CMS 024-02 ensures safety and tolerability for patients. In Mar 2007, CMS submitted application for Phase II clinical trial, which will be conducted between 2008 and 2009.